The place of recombinant activated factor VII in liver transplantation

International Anesthesiology Clinics

Volumn 44, Issue 3, 2006, Pages 99-110

  Gibbs, Neville M ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; WARFARIN; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FIBRINOLYSIS; HEART INFARCTION; HUMAN; INTRACRANIAL PRESSURE MONITORING; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; MEDICAL ETHICS; META ANALYSIS; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; BLEEDING; INTRACRANIAL PRESSURE; PATHOPHYSIOLOGY;

BLOOD LOSS, SURGICAL; FACTOR VIIA; HUMANS; INTRACRANIAL PRESSURE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; RECOMBINANT PROTEINS;

EID: 33747465874     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-200604430-00009     Document Type: Review

References (37)

1. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion. 2002;42:114-124.
2. Murkin JM. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice. Can J Anesth. 2002;49:S21-S26.
3. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Reviews. 2004;18:245-259.
4. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883-890.
5. Product information. NovoSeven, Novo nordisk, Copenhagen, Denmark (www.novonordisk.com).
6. Lisman T, Leebeck FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol. 2002;37:280-287.
7. Ozier Y, Steib A, Ickx B, et al. Haemostatic disorders during liver transplantation. Eur J Anaesth. 2001;18:208-218.
8. Caldwell SH, Chang C, Mack BG. Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology. 2004;39:592-598.
9. Lisman T, Leebeck FWG, Meijer K, et al. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology. 2002;35:616-621.
10. Roberts HR, Monroe DM III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hemat. 2004;41(Suppl 1):101-108.
11. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Hemost. 2001;85:958-965.
12. Porte RJ, Caldwell SH. The role of recombinant factor VIIa in liver transplantation. Liver Transplantation. 2005;11:872-874.
13. Van Theil DH, Brems J, Nadir A, et al. Liver transplantation for fulminant hepatic failure. J Gastroenterol. 2001;36:1-4.
14. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transplantation. 2003;9:138-143.
15. Brown JB, Emerick KM, Brown DL, et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. JPGN. 2003;37:268-272.
16. Pavese P, Bonadona A, Beaubien J, et al. FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases. Can J Anesth. 2005;52:26-29.
17. Kalicinski P, Kaminski A, Drewniak T, et al. Quick correction of hemostasis in two patients with fulminant hepatic liver failure undergoing liver transplantation by recombinant activated factor VIIa. Transplant Proc. 1999;31:378-379.
18. Markiewicz M, Kalicinski P, Kaminski P, et al. Acute coagulopathy after reperfusion of the liver graft in children: correction with recombinant activated factor VII. Transplant Proc. 2003;35:2318-2319.
19. Surudo T, Wojcicki P, Milkiewicz P, et al. Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation. Transplant Proc. 2003;35:2323-2325.
20. Hendriks HG, Meijer K, de Wolf JT, et al. Effects of recombinant activated factor VII on coagulation measured by thrombelastography in liver transplantation. Blood Coagul Fibrinolysis. 2002;13:309-313.
21. Eikelboom JW, Bird R, Blythe D, et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis. 2003;14:713-717.
22. Meijer K, Hendriks HG, de Wolf JT, et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis. 2003;14:169-174.
23. Nonthasoot B, Nivatongs S. Multiple doses of recombinant factor VIIa in orthotopic liver transplantation. Transplant Proc. 2003;36:427-428.
24. Hendriks HGD, Meijer K, de Wolf JThM, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation. 2001;71:402-405.
25. De Gasperi A, Baudo F, De Carlis L. Recombinant FVII in orthotopic liver transplantation (OLT): a preliminary single centre experience. Intensive Care Med. 2005;31:315-316.
26. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transplantation. 2005;11:895-900.
27. Lodge JPA, Jonas S, Jones RM, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation. 2005;11:973-979.
28. Lodge JPA, Jonas S, Oussoultzoglu E, et al. Recombinant coagulation factor VIIa in major liver resection. Anesthesiology. 2005;102:269-275.
29. Ozier Y, Pessione F, Samain E, et al. Institutional variability in transfusion practice for liver transplantation. Anesth Analg. 2003;97:671-679.
30. Kalicinski P, Markiewicz M, Kaminski A, et al. Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation. Pediatr Transplantation. 2005;9:299-304.
31. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325-1331.
32. Gibbs NM. Role of recombinant activated factor VII in the management of life-threatening coagulopathic bleeding. Anaesth Intensive Care. 2005;33:363-364.
33. Snook NJ, O'Beirne HA, Enright S, et al. Use of recombinant erythropoetin to facilitate liver transplantation in a Jehovah's witness. Br J Anaesth. 1996;76:740-753.
34. Detry O, Hornore P, Delwaide J, et al. Liver transplantation in Jehovah's a witness. Lancet. 1999;153:1680.
35. Detry O, De Roover A, Delwaide J, et al. Liver transplantation in Jehovah's witnesses. Transplant International. 2005;18:929-936.
36. Jabbour N, Gagandeep S, Peilin AC, et al. Recombinant human coagulation factor VIIa in Jehovah's witness patients undergoing liver transplantation. American Surgeon. 2005;71:175-179.
37. Oxford centre for evidence based medicine levels of evidence (www.cebm.net).